Search

everythinglearnresearchcommunity

for

Search:↓

Entospletinib effectively prevents eye and skin GVHD in mice.

CMV infection increases the risk of GvHD after bone marrow transplants.

Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Permanent hair loss after bone marrow transplant can be caused by chemotherapy or chronic graft-versus-host disease.

Some children who had stem cell transplants developed permanent hair loss, especially when treated with a drug called busulphan.

A woman's hair loss from graft versus host disease helps understand similar hair loss conditions.

A five-month-old boy with Omenn syndrome successfully recovered after a stem cell transplant with reduced intensity conditioning.

CD8+ T cells play a key role in graft-versus-host disease in certain mice models.

Older age is the main risk factor for hemorrhagic cystitis after stem cell transplants.

A man developed autoimmune issues after a transplant, improved with treatment, but died from leukemia relapse.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

A Japanese bone marrow transplant patient developed a rare skin cancer possibly linked to long-term use of the medication voriconazole.

A woman's sudden hair loss three years after a bone marrow transplant was a sign of chronic graft-versus-host disease but improved with treatment.

Most pediatric inpatients needed dermatology consultations for unspecified rashes and drug reactions, with varied treatments.

Patients often experience long-lasting changes to their hair after stem cell transplants.

A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.

Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.

Skin issues can indicate immune system problems.

EpiLife® media and younger donor age improve artificial skin model quality.

Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.

Graft-versus-host disease occurs when donor immune cells attack the recipient's body, causing skin, gut, and liver damage.

Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.

Black hairy tongue can be an early sign of graft-versus-host disease after stem cell transplants.

People with allergies or high eosinophil levels have a higher chance of severe hair loss from alopecia areata, and sudden hair loss can indicate chronic graft-versus-host disease.

Patients with graft-versus-host disease often have nail changes related to the nail matrix, with severity not linked to skin condition.

High amphiregulin in the skin is a bad sign for acute graft-versus-host disease.

Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.

Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.